Taha Merghoub

This study shows mutant p53 uses its C-terminal domain to reprogram PARP activity, enabling replication stress adaptation and metastasis in TNBC, and identifies mtp53 as a biomarker for PARP inhibitor and DNA-damaging therapy.

The paper identifies human myelocyte and metamyelocyte-stage neutrophils as immunosuppressive cells that promote cancer progression and suggests targeting them for immunotherapy.

The paper shows that TAD hierarchy restricts LTR activation, and its loss in cancer allows LTRs to act as alternative promoters, driving oncogene activation and transcriptional diversity.

This study identifies a pathogenic subpopulation of glioma-associated macrophages (mGAMs) linked to glioma progression through GRN analysis and functional validation.

This study explores factors influencing response and resistance to atezolizumab in urothelial cancer using multi-omic data, finding associations between TCR clonality and clinical outcomes.